What’s Behind MannKind Corporation (MNKD)’s Incredible Run? – Pfizer Inc. (PFE)

Page 1 of 2

After seeing MannKind Corporation (NASDAQ:MNKD) rocket upwards over the last week, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about what’s going on with the inhaled insulin drugmaker.

Max Macaluso: It’s been an amazing week for biotech company MannKind. Shares were up more than 4% yesterday, and shares are up more than 30% in the last 5 trading days. Big jumps with small, volatile stocks like this can be common, but the company actually didn’t have any news or catalysts. What’s happening here?

MannKind Corporation (NASDAQ:MNKD)Brian Orelli: Options expire this week, and we’re hitting all-time highs in the Dow. Also they’re getting ready to selecting a new pope in Rome.

None of those have anything to do with MannKind Corporation (NASDAQ:MNKD)’s fundamentals, but I wouldn’t be surprised if they’re influencing the stock price — minus the last one, unless investors are hoping a needle-phobic diabetic pope could be MannKind’s next spokesman — biotechs move for strange reasons.

There’s no reason that MannKind should be moving up this week, but it’s not all that surprising that it’s moved off its lows. The biotech has been dead money since its last FDA rejection. At some point, it becomes worth waiting for.

Macaluso: Usually biotech stocks have a mind of their own and don’t necessarily move with the Dow, but let’s take a look at how the iShares NASDAQ Biotechnology Index‘s performance correlates with the Dow.

IBB Chart

IBB data by YCharts.

Orelli: Not that surprising. As the generalist investors get excited, the biotech investors get really excited. Unfortunately it works the same way on the way down, too.

Macaluso: So MannKind Corporation (NASDAQ:MNKD) is now perched on a 52-week high. Looking at their cash position, do you think the company needs to raise more capital with a follow-on public offering?

Orelli: Do we really need to look at their cash position? They’ve got a billionaire founder with so much tied up in the company, there’s no way Al Mann is going to let his namesake go out of business at this point.

Macaluso: Well, let’s say does Afrezza get rejected by the FDA again — do you think Mr. Mann will put more money into the company? I know I’d probably call it quits.

Orelli: Me too. But I think Mann is more stubborn than either of us. It obviously depends on the nature of the rejection. Unless it’s clear the FDA will never approve it, I think he sticks with it.

Macaluso: OK, let’s circle back to my previous question: Do you think now is a good time to raise capital with a follow-on public offering?

Orelli: In general, I think biotechs should raise money when they can, not when they need it. By that standard, hitting a 52-week high falls in the “when you can” segment.

But MannKind has already diluted the heck out of its shareholders. Shares outstanding at the company are up 59% since the end of 2010, before the latest FDA rejection. Put another way, a dollar of earnings that a share was entitled to in 2010 — assuming MannKind becomes profitable someday — is only worth $0.63 today.

So I guess my answer is no; MannKind Corporation (NASDAQ:MNKD) shouldn’t raise capital. If the upcoming clinical trials fail — probably unlikely, but anything’s possible — and the company runs out of money, so be it. It makes more sense to raise after the binary events, when the share price is hopefully higher and dilution won’t be quite as painful.

Macaluso: It can be dangerous to assume a drug will get approved because FDA decisions are unpredictable. Take Novo Nordisk A/S (ADR) (NYSE:NVO)‘s Tresiba, for instance. That drug was already approved in Europe and everyone believed it would be a shoo-in with the FDA, but it was handed a complete response letter.

Orelli: Yeah, buying after the run-up is almost never a good idea because in the risk-reward equation, you’ve lost some reward, but the risk is still the same.

Macaluso: So, Brian, what’s the next catalyst that investors need to watch?

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!